LON:TILS Tiziana Life Sciences (TILS) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Tiziana Life Sciences Stock (LON:TILS) Get Tiziana Life Sciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume297,127 shsAverage Volume522,223 shsMarket Capitalization£113.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited. Read More Receive TILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TILS Stock News HeadlinesTiziana Life Sciences Completes Enrollment in Phase 2 INFORM-MS Trial for Intranasal ForalumabJune 25, 2026 | tipranks.comTiziana Life Sciences Chair Boosts Stake as Foralumab Trials AdvanceJune 15, 2026 | tipranks.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 14 at 1:00 AM | Profits Run (Ad)Tiziana Life Sciences to Showcase Intranasal Foralumab Progress at Jefferies Healthcare ConferenceMay 28, 2026 | tipranks.comTiziana Life Sciences Completes Enrollment in Phase 2 Intranasal Foralumab MS TrialMay 21, 2026 | tipranks.comTiziana Life Sciences Reports Positive Expanded Access Data for Intranasal Foralumab in Progressive MSMay 19, 2026 | tipranks.comTiziana Life Sciences Posts Early PET Data Showing Reduced Brain Inflammation in MSA Trial of Intranasal ForalumabMay 14, 2026 | tipranks.comTiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal ForalumabApril 16, 2026 | tipranks.comSee More Headlines TILS Stock Analysis - Frequently Asked Questions How were Tiziana Life Sciences' earnings last quarter? Tiziana Life Sciences PLC (LON:TILS) posted its earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.00) by $1.40. How do I buy shares of Tiziana Life Sciences? Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Tiziana Life Sciences (TLSA), Meta Platforms (META), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings9/30/2020Today7/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:TILS Previous SymbolLON:ADI CIKN/A Webwww.tizianalifesciences.com Phone+44-20-74952379FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.36 Current Ratio6.54 Quick Ratio6.41 Sales & Book Value Annual Sales-£3.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.28 Book ValueGBX 23.50 per share Price / BookN/AMiscellaneous Outstanding Shares194,612,000Free FloatN/AMarket Cap£113.85 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (LON:TILS) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredConfirm Your Name Before the Letter Goes OutAmericans who believe in real retirement protection are adding their names to a statement going out to Washing...American Alternative | SponsoredThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...Priority Gold | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TILS Stock Alerts